Regeneron Pharmaceuticals Inc (REGN), Ampio Pharmaceuticals, Inc. (AMPE): Is This Eye Drug Worth The Hype?

Conclusion

Hopefully you see the Eylea’s upside and why Regeneron has been awarded such a large valuation. With just one indication sales are already projected to be over $1 billion in 2013. In addition to mCNV, the company is also testing Eylea in three other trials. Combined, analysts expect Eylea to easily top $4 billion in annual sales.

While my goal was to discuss Eylea and the progress it has seen in the market, I must also mention Regeneron’s other projects: Zaltrap for colorectal cancer, and a bacterial drug Aralyst. In its pipeline, the company has a cholesterol drug called Alirocumab currently in Phase III trials. Much like Eylea, it is superior to its competition, and has projected sales north of $5 billion.

The bottom line is this is a wonderful company with cutting-edge products that will see growth for many years to come. In many ways, we are seeing the second coming of Gilead Sciences, although possibly better, and I suggest you take a long hard look.

Sherrie Stone owns shares of Regeneron Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned.

The article Is This Eye Drug Worth The Hype? originally appeared on Fool.com and is written by Sherrie Stone.

Sherrie is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.